The Suppression of Metastases and the Change in Host Immune Response after Low-Dose Total-Body Irradiation in Tumor-Bearing Rats

1999 ◽  
Vol 151 (6) ◽  
pp. 717 ◽  
Author(s):  
Seiko Hashimoto ◽  
Hiroki Shirato ◽  
Masuo Hosokawa ◽  
Takeshi Nishioka ◽  
Yasuhiro Kuramitsu ◽  
...  
Keyword(s):  
Immune Response ◽  
Total Body Irradiation ◽  
Low Dose ◽  
Host Immune Response ◽  
Tumor Bearing ◽  
Total Body

Low-Dose Total Body Irradiation in Non-Hodgkin Lymphoma

1990 ◽  
Vol 13 (4) ◽  
pp. 280-284 ◽  
Author(s):  
W. J. De Neve ◽  
M. L. M. Lybeert ◽  
J. H. Meerwaldt
Keyword(s):  
Hodgkin Lymphoma ◽  
Total Body Irradiation ◽  
Low Dose ◽  
Non Hodgkin Lymphoma ◽  
Total Body

Hemopoiesis in pregnant beagles following low-dose total-body irradiation and surgery

1983 ◽  
Vol 39 (8) ◽  
pp. 864-866 ◽  
Author(s):  
S. R. Weinberg ◽  
A. C. Bakarich ◽  
G. D. Ledney ◽  
M. P. McGarry ◽  
T. J. MacVittie
Keyword(s):  
Total Body Irradiation ◽  
Low Dose ◽  
Total Body

Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma.

1996 ◽  
Vol 14 (2) ◽  
pp. 565-571 ◽  
Author(s):  
L B Travis ◽  
J Weeks ◽  
R E Curtis ◽  
J T Chaffey ◽  
M Stovall ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Total Body Irradiation ◽  
Hodgkin’S Lymphoma ◽  
Low Dose ◽  
Alkylating Agents ◽  
Salvage Treatment ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Total Body

PURPOSE Low-dose total body irradiation (TBI) is used to treat non-Hodgkin's lymphoma (NHL) and several other malignancies. Large volumes of bone marrow and other tissue receive considerable exposure, but few studies have quantified late carcinogenic sequelae. PATIENTS AND METHODS A cohort of 61 2-year survivors of NHL treated initially with low-dose TBI was monitored for second cancer occurrence. Data on primary and subsequent therapy were collected, and cumulative dose of radiation to active bone marrow (ABM) (median, 5.2 Gy) was reconstructed. RESULTS Thirteen second primary cancers occurred. Four patients developed acute nonlymphocytic leukemia (ANLL), which represents a relative risk (RR) of 117 (95% confidence interval [CI], 31.5 to 300) compared with population rates. A fifth patient was diagnosed with myelodysplastic syndrome (MDS). All five patients with secondary hematologic malignancies subsequently received salvage treatment, with either alkylating agents alone (n = 1) or combined modality therapy (CMT) (n = 4). Overall, eight solid tumors were observed (RR = 2.0; 95% CI, 0.9 to 4.0). The 15-year cumulative risks of all second cancers and secondary ANLL were 37% and 17%, respectively. CONCLUSIONS Despite the small number of subjects, a considerable risk of leukemia was observed among patients treated with low-dose TBI in combination with CMT including alkylating agents. Based on these results, approximately eight to nine excess ANLLs might be expected to occur among 100 NHL patients treated with low-dose TBI and salvage treatment and followed-up for 15 years.

Clinical significance of low-dose total body irradiation in HLA-mismatched reduced-intensity stem cell transplantation

2019 ◽  
Vol 54 (8) ◽  
pp. 1327-1336 ◽  
Author(s):  
Shin-ichiro Fujiwara ◽  
◽  
Junya Kanda ◽  
Raine Tatara ◽  
Hiroyasu Ogawa ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Clinical Significance ◽  
Total Body Irradiation ◽  
Low Dose ◽  
Total Body ◽  
Reduced Intensity

scholarly journals Syngeneic and allogeneic bone marrow engraftment after total body irradiation: dependence on dose, dose rate, and fractionation

Blood ◽  
1991 ◽  
Vol 77 (3) ◽  
pp. 661-669 ◽  
Author(s):  
JD Down ◽  
NJ Tarbell ◽  
HD Thames ◽  
PM Mauch
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Radiation Dose ◽  
Dose Rate ◽  
Dose Response ◽  
Total Body Irradiation ◽  
Low Dose ◽  
Allogeneic Bone ◽  
Low Dose Rate ◽  
Total Body

Abstract Murine bone marrow chimera models were used to assess the efficacy of host total body irradiation (TBI) given at different doses, dose rates, and fractionation schemes in providing for engraftment of syngeneic and allogeneic bone marrow. B6-Hbbd congenic and LP mice, respectively, were used as donors (10(7) bone marrow cells) for syngeneic and allogenic (H-2 compatible) transplantation in standard B6 recipients. Stable marrow chimerism was determined from host and donor stem cell- derived hemoglobin phenotypes (Hbbs and Hbbd) on gel electrophoresis at 3 months posttransplant. Partial engraftment of syngeneic marrow was seen at single doses as low as 2 Gy, with the donor component increasing steadily with increasing TBI dose to a level of 100% at 7 Gy. Immunologic resistance of the host appeared to prevent allogeneic engraftment until 5.5 Gy. A very steep radiation dose response was then observed so that the level of chimerism with 6 Gy and above became comparable with syngeneic engraftment. Low dose rate (5 cGy minute-1) and fractionated TBI required higher total doses for equivalent engraftment (radiation dose-sparing) in both syngeneic and allogenic bone marrow transplantation. This displacement in the dose-response curve on fractionation was seen with interfraction intervals of 3 and 6 hours. A further dose-sparing effect was observed on extending the interval to 18 and 24 hours, but only for allogeneic transplantation, and may therefore be related to recovery of immune-mediated graft resistance. The involvement of multiple target cell populations in determining allogenic engraftment rendered the application of the linear-quadratic model for radiation cell survival problematic in this case. The recovery in dose when low dose rate and 6-hour interfraction intervals were applied in either syngeneic or allogeneic BMT is consistent with appreciable sub-lethal damage repair in the primitive self-renewing stem cell population of the host marrow. These results contrast with the poor repair capacity of the 11-day spleen colony- forming units (CFUs) population after fractionated irradiation and support the notion that ablation of early stem cells in the pre-CFUs compartment is essential for long-term marrow engraftment.

Sign in / Sign up

Export Citation Format

Share Document